Pacing-lead sheath method–directed right atrial septal endomyocardial biopsy in identifying arrhythmogenic right ventricular cardiomyopathy: A case report Authors: Youyou Chen, Qingbo Lv, Chao Chen, Jiling Zeng, Yang Ye Published: 2026 Key Teaching Points •When patients present with unexplained sick sinus syndrome associated with right heart abnormalities, arrhythmogenic right ventricular cardiomyopathy (ARVC) should be considered.•Cardiac endomyocardial biopsy (EMB) provides a safe and effective approach for confirming the diagnosis of ARVC.•For the first time, this study found a pathological feature of ARVC present in the right atrial tissue via atrial EMB, thereby confirming a diagnosis of ARVC. Key Teaching Points •When patients present with unexplained sick sinus syndrome associated with right heart abnormalities, arrhythmogenic right ventricular cardiomyopathy (ARVC) should be considered.•Cardiac endomyocardial biopsy (EMB) provides a safe and effective approach for confirming the diagnosis of ARVC.•For the first time, this study found a pathological feature of ARVC present in the right atrial tissue via atrial EMB, thereby confirming a diagnosis of ARVC. •When patients present with unexplained sick sinus syndrome associated with right heart abnormalities, arrhythmogenic right ventricular cardiomyopathy (ARVC) should be considered. When patients present with unexplained sick sinus syndrome associated with right heart abnormalities, arrhythmogenic right ventricular cardiomyopathy (ARVC) should be considered. •Cardiac endomyocardial biopsy (EMB) provides a safe and effective approach for confirming the diagnosis of ARVC. Cardiac endomyocardial biopsy (EMB) provides a safe and effective approach for confirming the diagnosis of ARVC. •For the first time, this study found a pathological feature of ARVC present in the right atrial tissue via atrial EMB, thereby confirming a diagnosis of ARVC. For the first time, this study found a pathological feature of ARVC present in the right atrial tissue via atrial EMB, thereby confirming a diagnosis of ARVC. Introduction Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare genetic disorder involving fibrofatty replacement of myocardial tissue,1 leading to ventricular arrhythmia and an increased risk of sudden cardiac death.2 Diagnosis remains challenging because of heterogeneous clinical presentations and often requires multimodal evaluation, including imaging, electrocardiography, and histopathological analysis.3, 4, 5 In this report, we present a case of a middle-aged male patient with right heart enlargement, in whom the diagnosis of ARVC was definitively confirmed through endomyocardial biopsy (EMB). Right ventricular (RV) and atrial septal sampling was performed during cardiac implantable electronic device (CIED) implantation using our pacing lead sheath method (L-S-M). Case report We report the case of a 45-year-old man with no significant cardiovascular disease history or risk factors who complained of 3 weeks of recurrent dizziness and chest discomfort. Notably, the patient’s father had died of sudden cardiac death. Upon pursuing medical assistance, vital signs were stable, with a blood pressure of 142/67 mm Hg and a heart rate of 75 beats/min. The physical examination was unremarkable. The 12-lead electrocardiogram revealed a slow junctional escape rhythm or low atrial escape rhythm, with occasional supraventricular beats associated with intraventricular conduction delay. Accelerated idioventricular rhythm was also present, along with incomplete dissociation of atrioventricular activity (Figure 1A). A 24-hour Holter electrocardiogram monitoring revealed sinus arrest, with the longest pause lasting 3.7 seconds (Figure 1B). Transthoracic echocardiography demonstrated enlargement of the right heart and left atrium, with mild reduction in the apical motion of the RV (Figure 2A). The RV outflow tract measured 41.9 mm (Figure 2B). The left ventricular ejection fraction was 65%, left ventricular end-diastolic diameter 49.8 mm, left ventricular end-systolic dimension 32.3 mm, and RV area change fraction 43.6%. Blood troponin and myocardial enzyme profiles showed no significant abnormalities. In addition, coronary angiography revealed no significant stenosis in the coronary arteries. Because of the RV abnormality observed on echocardiography, the patient was admitted for further cardiac magnetic resonance (CMR) imaging evaluation, which revealed an enlarged right atrium (65 mm) and RV, with reduced motion at the RV apex (Figure 2C and 2D; Supplemental Video 1), an RV end-diastolic volume/body surface area ratio of 120.49 mL/m2, and a RV ejection fraction of 50.63%. These findings were consistent with one of the major diagnostic criteria of CMR imaging for ARVC. The patient was referred for CIED implantation. During CIED implantation, we used a novel L-S-M for EMB via the subclavian or axillary vein.6 The 3830 lead (Medtronic) was delivered through a 315 sheath (Medtronic) to the right atrial and ventricular septa (Figure 3A). For the right atrial septum biopsy, under left anterior oblique projection, the 3830 lead was screwed into the septal myocardium, and its orientation toward the spine was confirmed in the left anterior oblique 45° view. The lead was deeply inserted clockwise by 4–5 turns. The lead was then gently and rapidly unscrewed, revealing myocardial tissue retained at the tip. This process was repeated twice during the atrial biopsy. We also performed the ventricular EMB using a similar approach. After the EMB, the 3830 lead was implanted into the right atrial septum (Figure 3B). The histopathological results in the right atrial septum indicated that <60% of the myocardial tissue remained viable. Masson’s trichrome staining revealed substantial fibrous connective tissue proliferation within the myocardial tissue (Figure 4A and 4B), consistent with one of the major pathological criteria for ARVC. The patient was discharged in improved condition after a 5-day hospitalization. During follow-up 3 months after discharge, the patient’s symptoms, including chest tightness and dizziness, significantly improved with the aforementioned treatment.Figure 1A: 12-Lead electrocardiography. B: 24-Hour Holter electrocardiography.Figure 2Echocardiography and cardiac magnetic resonance (CMR) imaging examination. A and B: Right heart dilation, as observed in the echocardiographic long-axis view and apical 4-chamber view. C and D: CMR imaging in the 2- and 4-chamber views revealed right heart enlargement, accompanied by hypokinesis at the right ventricular apex. LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle.Figure 3Pacing lead sheath method–directed right atrial septal endomyocardial biopsy (EMB) during cardiac implantable electronic device (CIED) implantation. A: Under the fluoroscopic right anterior oblique view, the 3830 lead was advanced through a 315 sheath into the right atrial septum for complete EMB. B: Under the fluoroscopic left anterior oblique view, the CIED was deployed, with the 3830 lead securely anchored in the right atrial septum.Figure 4Pathological staining of endomyocardial biopsy. A: Hematoxylin and eosin staining (original magnification ×20). The black arrow highlights the biopsy site, where histological examination revealed fibrofatty replacement of the right atrial myocardium, a characteristic finding consistent with the diagnosis of arrhythmogenic right ventricular cardiomyopathy. B: Masson’s trichrome staining (original magnification ×20), showing substantial fibrous connective tissue proliferation within the myocardial tissue. The red arrow shows fibrofatty tissue replacement with myocardial atrophy. A: 12-Lead electrocardiography. B: 24-Hour Holter electrocardiography. Echocardiography and cardiac magnetic resonance (CMR) imaging examination. A and B: Right heart dilation, as observed in the echocardiographic long-axis view and apical 4-chamber view. C and D: CMR imaging in the 2- and 4-chamber views revealed right heart enlargement, accompanied by hypokinesis at the right ventricular apex. LA = left atrium; LV = left ventricle; RA = right atrium; RV = right ventricle. Pacing lead sheath method–directed right atrial septal endomyocardial biopsy (EMB) during cardiac implantable electronic device (CIED) implantation. A: Under the fluoroscopic right anterior oblique view, the 3830 lead was advanced through a 315 sheath into the right atrial septum for complete EMB. B: Under the fluoroscopic left anterior oblique view, the CIED was deployed, with the 3830 lead securely anchored in the right atrial septum. Pathological staining of endomyocardial biopsy. A: Hematoxylin and eosin staining (original magnification ×20). The black arrow highlights the biopsy site, where histological examination revealed fibrofatty replacement of the right atrial myocardium, a characteristic finding consistent with the diagnosis of arrhythmogenic right ventricular cardiomyopathy. B: Masson’s trichrome staining (original magnification ×20), showing substantial fibrous connective tissue proliferation within the myocardial tissue. The red arrow shows fibrofatty tissue replacement with myocardial atrophy. Discussion In this case, according to the diagnostic criteria for ventricular morphological and functional abnormalities, CMR imaging showed mild hypokinesia of the RV apex along with RV end-diastolic volume/body surface area ratio > 110 mL/m2, meeting a major criterion for ARVC. EMB is considered an important diagnostic tool for evaluating cardiomyopathies, myocarditis, unexplained ventricular arrhythmias, and cardiac involvement in systemic diseases.7 However, the optimal timing for EMB remains uncertain, and it is often avoided during CIED implantation.8,9 To address this concern, we conducted an EMB concurrently with the implantation of a defibrillator. The standard EMB procedure, which is routinely performed using specialized myocardial biopsy forceps, is associated with several clinically significant complications. These complications include, but are not limited to, cardiac tamponade necessitating pericardiocentesis, thromboembolism, severe arrhythmias, and valvular trauma.10 We employed an alternative method by using a cardiac pacing lead instead of traditional biopsy forceps. In our clinical experience, L-S-M has achieved a 100% success rate for RV septal EMB without any major complications. This approach aimed to shorten the diagnosis time, clarify the patient’s pathological diagnosis, and reduce tricuspid valve injury. On the basis of the patient’s echocardiography and CMR imaging findings, which indicated significant biatrial enlargement in addition to RV dilation, the decision was made to perform an additional right atrial biopsy. Clinically, atrial biopsies are not routinely performed, given the risk of perforation of the thin atrial wall.11 Although successful and safe sampling of the interatrial septum can be achieved with the guidance of intracardiac echocardiography and fluoroscopy.12,13 Building on our previous experience with ventricular myocardial biopsy, we extended the procedure to include atrial sampling. We safely performed both atrial septal and ventricular septal EMBs in this patient using L-S-M during implantable cardioverter-defibrillator implantation, without requiring additional tools. No pericardial effusion was observed after the EMB. The atrial biopsy, but not ventricular biopsy, specimens confirmed the diagnosis of ARVC, and no complications were observed during and after the procedure. The right atrium yielded positive results, and this case demonstrated that the relevant pathological changes were found in both atrial and ventricular tissues. Conclusion Our case demonstrates the use of L-S-M–directed right atrial septal EMB to confirm ARVC, fulfilling CMR imaging and pathological criteria. The procedure was performed safely during CIED implantation without requiring additional tools. Disclosures The authors have no conflicts of interest to disclose.